Centessa Pharmaceuticals Plc (DE:260)
NASDAQ:260
260 Stock Chart & Stats
€32.60
€0.60(3.87%)
At close: 4:00 PM EST
€32.60
€0.60(3.87%)
Day’s Range― - ―
52-Week Range€10.50 - €34.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.32B
Enterprise Value€6.10B
Total Cash (Recent Filing)€276.59M
Total Debt (Recent Filing)€7.37M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Aug 17, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.78
Shares Outstanding154,728,970
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)6.44
Price to Sales (P/S)226.28
P/FCF Ratio-17.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€36.63Price Target Upside12.36% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)-1.46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetExtremely low leverage gives Centessa durable financial flexibility uncommon for development-stage biotechs. It reduces near-term refinancing risk, supports continued R&D spending or structured M&A outcomes, and preserves optionality while clinical programs advance.
Strategic Acquisition By Eli LillyThe Lilly transaction is a structural validation of Centessa's OX2R-focused pipeline and reduces standalone execution risk. Integration into a large commercial R&D engine increases the odds of late-stage development, funding, and commercialization for its sleep-therapy assets.
Regulatory Incentive For Lead AssetOrphan designation for cleminorexton provides lasting regulatory and development advantages—such as incentives and exclusivity potential—that strengthen the long-term commercial and regulatory profile of the asset and improve its strategic value to potential acquirers or partners.
Bears Say
No Trailing RevenueAbsence of recurring revenue is a fundamental constraint: the company depends entirely on external financing or a transaction to fund operations. This structural lack of operating cash inflows increases vulnerability to funding gaps and limits independent runway for program development.
High Cash BurnSustained, sizable negative operating and free cash flow creates persistent funding needs and raises the probability of dilutive financing or asset sales absent consummation of the Lilly deal. Heavy burn pressures capital allocation and can force strategic trade-offs in R&D prioritization.
Deeply Negative Returns On EquityA materially negative ROE signals poor capital efficiency and persistent value destruction. Continued losses at this scale will gradually erode the equity base, weakening long-term balance sheet stability and limiting strategic flexibility if adverse clinical or regulatory outcomes arise.
Centessa Pharmaceuticals News
260 FAQ
What was Centessa Pharmaceuticals Plc’s price range in the past 12 months?
Centessa Pharmaceuticals Plc lowest stock price was €10.50 and its highest was €34.00 in the past 12 months.
What is Centessa Pharmaceuticals Plc’s market cap?
Centessa Pharmaceuticals Plc’s market cap is €5.32B.
When is Centessa Pharmaceuticals Plc’s upcoming earnings report date?
Centessa Pharmaceuticals Plc’s upcoming earnings report date is Aug 17, 2026 which is in 65 days.
How were Centessa Pharmaceuticals Plc’s earnings last quarter?
Centessa Pharmaceuticals Plc released its earnings results on May 05, 2026. The company reported -€0.337 earnings per share for the quarter, beating the consensus estimate of -€0.35 by €0.013.
Is Centessa Pharmaceuticals Plc overvalued?
According to Wall Street analysts Centessa Pharmaceuticals Plc’s price is currently Undervalued.
Does Centessa Pharmaceuticals Plc pay dividends?
Centessa Pharmaceuticals Plc does not currently pay dividends.
What is Centessa Pharmaceuticals Plc’s EPS estimate?
Centessa Pharmaceuticals Plc’s EPS estimate is -0.35.
How many shares outstanding does Centessa Pharmaceuticals Plc have?
Centessa Pharmaceuticals Plc has 154,728,970 shares outstanding.
What happened to Centessa Pharmaceuticals Plc’s price movement after its last earnings report?
Centessa Pharmaceuticals Plc reported an EPS of -€0.337 in its last earnings report, beating expectations of -€0.35. Following the earnings report the stock price went up 0.606%.
Which hedge fund is a major shareholder of Centessa Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in DE:260
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Centessa Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€36.63 (12.36% Upside)
€36.63 (12.36% Upside)
Blogger Sentiment
Bullish
DE:260 Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
218.41%
12-Months-Change
Fundamentals
Return on Equity
-60.37%
Trailing 12-Months
Asset Growth
21.58%
Trailing 12-Months
Company Description
Centessa Pharmaceuticals Plc
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
260 Stock 12 Month Forecast
Average Price Target
€36.63
▲(12.36% Upside)
Technical Analysis
Options Prices
Currently, No data available
---